Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Literature
1.
2.
Rosario PW, Mineiro Filho AF, Prates BS, Silva LC, Calsolari MR. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid. 2012;22:1140-3.CrossRef
3.
Mourão GF, Rosario PW, Calsolari MR. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation. Endocr Relat Cancer. 2016;23:47-52.CrossRef
4.
Rosario PW, Mourão G, Calsolari MR. Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine. J Endocrinol Invest. 2019;42:687-92.CrossRef
5.
Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Chami L, Travagli JP, et al. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer. 2011;18:R29-40.PubMed
6.
Rosario PW, Mourão GF, Calsolari MR. Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk ‘with higher risk features’. Clin Endocrinol (Oxf). 2016;85:453-8.CrossRef
7.
Rosario PW, Xavier AC, Calsolari MR. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid. 2011;21:49-53.CrossRef
8.
Rosario PW, Mourão GF, Calsolari MR. Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin. Nucl Med Commun. 2016;37:1024-9.CrossRef
9.
Giovanella L, Avram AM, Clerc J, Hindié E, Taïeb D, Verburg FA. Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy? Eur J Nucl Med Mol Imaging. 2018;45:2155-8.CrossRef
Metadata
Title
Postoperative Unstimulated Thyroglobulin for the Decision to Use Radioactive Iodine in Patients with Low- or Intermediate-Risk Papillary Thyroid Carcinoma
Author
Pedro Weslley Rosario, MD
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07722-z

Other articles of this Special Issue 3/2019

Annals of Surgical Oncology 3/2019 Go to the issue

ASO Author Reflections

ASO Author Reflections: Use of Breast Imaging After Treatment for Locoregional Breast Cancer (AFT-01)

ASO Author Reflections

ASO Author Reflections: A New Look at the Clinical Significance of MVI in Hepatocellular Carcinoma

ASO Author Reflections

ASO Author Reflections: TNM 8th Edition: Stage I Non-small Cell Lung Cancer—Free from Recurrence and Adjuvant Therapy? How to Predict?

ASO Author Reflections

ASO Author Reflections: Dissecting the Risk and Impact of Venous Thromboembolism During Neoadjuvant Treatment and the Subsequent Perioperative Period for Patients With Pancreatic Adenocarcinoma

ASO Author Reflections

ASO Author Reflections: Amputation for Extremity Sarcoma

ASO Author Reflections

ASO Author Reflections: Analysis of PD-L1 Expression and Immunoscore in Colorectal Cancer